ALK Positive Lung Cancer: Clinical Profile, Practice and Outcomes in a Developing Country.

ABSTRACT:

Objectives

To evaluate the performance and treatment profile of advanced EML4-ALK positive Non-small cell lung cancer (NSCLC) patients in a developing country with potentially restricted access to Crizotinib.

Materials and methods

A retrospective analysis of advanced ALK positive NSCLC patients who were treated from June 2012 to September 2015 was conducted. The primary goal was to evaluate outcomes of advanced ALK positive NSCLC in our practice and examine the logistic constraints in procuring Crizotinib.

Results

94 patients were available for analysis. 21 (22.3%) patients were started on Crizotinib upfront, 60 (63.8%) on chemotherapy, 10 (10.6%) on Tyrosine kinase inhibitors (in view of poor PS) and 3 (3.2%) patients were offered best supportive care. Reasons for no

SUBMITTER: Noronha V 

PROVIDER: S-EPMC5026380 | biostudies-literature | 2016

REPOSITORIES: biostudies-literature